Efdamrofusp Alfa (IBI302)

Product

Last mentioned: Mar 24, 2026

Timeline

  1. NDA Submission

    Anticipated filing of the New Drug Application with the NMPA.

  2. Primary Endpoint Met

    Innovent announces positive top-line results from the Phase 3 STAR study.

  3. STAR Study Initiation

    Commencement of the Phase 3 registration trial across multiple sites in China.

  4. Phase 2 Completion

    Phase 2 data showed promising safety and efficacy in nAMD patients.

Stories mentioning Efdamrofusp Alfa (IBI302) 1

clinical-trial Very Bullish

Innovent's IBI302 Hits Phase 3 Goal, Pioneering Extended nAMD Care in China

Innovent Biologics' IBI302 (efdamrofusp alfa) successfully met its primary endpoint in the Phase 3 STAR registration trial for neovascular age-related macular degeneration. As the first domestically developed extended-interval treatment in China, it represents a significant shift toward reducing the injection burden for millions of patients.

2 sources